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GUEST EDITORIAL

Tightening Our Belts in the New Healthcare Economy
Coming soon: austerity in healthcare.
During the “Great Recession” of
recent years, those of us employed in
healthcare have largely avoided the tumult
experienced in other sectors, like housing
and finance. Jobs have actually been
added to the healthcare sector, payments
for healthcare services have remained
stable enough to sustain the system, and
new opportunity presents itself with more
Americans likely to obtain coverage as a
result of the Affordable Care Act (ACA).
Let’s face it, we’ve been quite fortunate.
However, from a budgetary standpoint,
we face unprecedented challenges. The
fiscal cliff legislation, passed at the 11th
hour on January 1, preserves payments
to physicians but cuts payments for endstage renal disease (estimated savings
$4.9 billion), resets the base for certain
types of Medicaid payments to hospitals
(estimated savings $4.2 billion), and
recoups past overpayments to hospitals
through documentation and coding
adjustments (estimated savings $10.5
billion). Additional healthcare spending
reductions are likely in coming months
when Congress renews its battle over
increasing the debt ceiling, and tradeoffs in
the form of more spending cuts are already
part of the political discussion.
The addition of newly-covered patients
under ACA, coupled with these budgetary
challenges, means the system will have
to provide more care for less money.
Meanwhile, the overhead cost of simply
“doing business”—compliance with
regulations, performance measures, and
accreditation standards—seems to be
going up. As someone who has grown
accustomed to stability, these changes
are fast, furious, and frightening. What
will be the key to our success in this new
era of healthcare? I’ve thought about this
and keep coming back to the same word:

efficiency. Never has there been a greater
need to understand how to best spend our
healthcare dollars. We need to recognize
what are the most resource intensive
components of care, and determine
whether there are ways to deliver those
components more cheaply or quickly—all
while maintaining our shared priority of
excellence in patient care.
As an applied health economics researcher
for 15 years, I’m seeing the “efficiency”
theme play out every day in my work. The
overall demand for cost data is increasing,
but the nature of the questions to be
answered by these data is changing. A
decade ago, a common question was: “Is
the treatment cost effective?” Now, the
usual questions are: “What will it cost to
implement this treatment?”, “How can the
treatment be implemented most efficiently?”
and “What will be the return on investment
if we implement this treatment?” In other
words, the conversation is shifting away
from a willingness to accept increased costs
for treatments that are more effective, and
towards purely budget-based and operational
decision making aimed at determining
how to do things more affordably. From
a scientific perspective, this shift suggests
that cost-benefit analyses will emerge as
the most relevant type of cost analysis
(the goal being to determine whether
investment in a treatment results in net
financial benefits, i.e., savings, elsewhere in
the system), with the more traditional costeffectiveness analyses (where one considers
the incremental cost per incremental health
benefit compared to the standard of care)
potentially falling out of favor.
Consider, for example, a key area of
pharmaceutical innovation -- the new oral
anticoagulants dabigatran, rivaroxaban
and apixaban. While real-world evidence
on the effectiveness and safety of these
drugs is still emerging, from an economic

standpoint the key question is whether
the higher price of these drugs is offset
by measurable efficiencies in the form
of reduced patient monitoring and
counseling requirements when compared
to warfarin. Next, consider improved
testing for diagnosis and staging of
prostate cancer. Here the question is also
whether the additional costs of the test
are offset by more efficiently targeting
men who need treatment, and avoiding
unnecessary treatment in men who are
unlikely to benefit. Finally, consider patient
support programs for seniors with mildto-moderate dementia. Again, the key
question is whether investment in coaching
the patient and their family caregivers
-- perhaps even making infrastructural
improvements to the home -- could delay
formal paid caregiving and admission to
long-term care. Just start looking around
at the innovations being considered in
your area of healthcare and you will notice
this shift which now spans across drugs,
devices, diagnostic assays, and patient
support programs.
Members of the healthcare community, we
need to collectively acknowledge this new
reality and embrace it because, short of a
miraculous economic recovery, healthcare
budget cutting will present very difficult
challenges. It may be politically unpopular
for the government to formally support or
mandate cost analyses, but we desperately
need these data in order to understand how
to treat patients most efficiently. Those of
us in the trenches can and will be doing this
work—we no longer have a choice. I hope
you will join me in supporting it as a key
component of the critical real-world evidence
necessary to inform healthcare decisions. 
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